Peptides and peptide conjugates: therapeutics on the upward path
- PMID: 22917246
- DOI: 10.4155/fmc.12.76
Peptides and peptide conjugates: therapeutics on the upward path
Abstract
The main benefit of natural peptides, peptide analogs and newly designed peptides as therapeutics, lies in their high selectivity and affinity, which are frequently in the nanomolar range. New drugs targeting protein-protein interactions often require larger interaction sites than small molecules can offer. Thus, many peptidic drugs are already applied in therapy at the current state. The next generation of peptide-based therapeutic agents is currently on its way from basic research to clinical studies and eventually to the pharmaceutical market. Development of more robust and long-lasting drugs owing to well-known and new stabilization strategies is yielding novel and continuously improving peptide drugs. The introduction of smart linkers that exhibit stability towards blood plasma but intracellular lability will lead to target-oriented activity, which might successfully decrease side effects. In this review, peptidic therapeutics on the market, in clinical studies and some of those in basic research are characterized. Stabilization strategies and intelligent linkers are discussed with respect to their use in peptide drug therapy.
Similar articles
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
Peptide-based drug design: here and now.Methods Mol Biol. 2008;494:1-8. doi: 10.1007/978-1-59745-419-3_1. Methods Mol Biol. 2008. PMID: 18726565
-
Current strategies for the development of peptide-based anti-cancer therapeutics.J Pept Sci. 2005 Nov;11(11):713-26. doi: 10.1002/psc.717. J Pept Sci. 2005. PMID: 16138387 Review.
-
Peptides as a platform for targeted therapeutics for cancer: peptide-drug conjugates (PDCs).Chem Soc Rev. 2021 Feb 15;50(3):1480-1494. doi: 10.1039/d0cs00556h. Chem Soc Rev. 2021. PMID: 33346298 Review.
-
Current trends in the clinical development of peptide therapeutics.IDrugs. 2009 Dec;12(12):779-84. IDrugs. 2009. PMID: 19943221 Review.
Cited by
-
Identification and Characterization of Antigenic Properties of Schistosoma japonicum Heat Shock Protein 90α Derived Peptides.Pathogens. 2022 Oct 26;11(11):1238. doi: 10.3390/pathogens11111238. Pathogens. 2022. PMID: 36364989 Free PMC article.
-
Lipidization as a tool toward peptide therapeutics.Drug Deliv. 2023 Dec;30(1):2284685. doi: 10.1080/10717544.2023.2284685. Epub 2023 Nov 27. Drug Deliv. 2023. PMID: 38010881 Free PMC article. Review.
-
Novel Assay Platform to Evaluate Intracellular Killing of Mycobacterium tuberculosis: In Vitro and In Vivo Validation.Front Immunol. 2021 Nov 12;12:750496. doi: 10.3389/fimmu.2021.750496. eCollection 2021. Front Immunol. 2021. PMID: 34867981 Free PMC article.
-
Biological Characterization of Computationally Designed Analogs of peptide TVFTSWEEYLDWV (Pep2-8) with Increased PCSK9 Antagonistic Activity.Sci Rep. 2019 Feb 20;9(1):2343. doi: 10.1038/s41598-018-35819-0. Sci Rep. 2019. PMID: 30787312 Free PMC article.
-
Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy.Molecules. 2021 Oct 5;26(19):6042. doi: 10.3390/molecules26196042. Molecules. 2021. PMID: 34641586 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
